SJ Lee, Orum Therapeutics CEO
November 6, 2023 07:00 AM EST
Startups
Deals
Pharma

Bris­tol My­ers buys Orum Ther­a­peu­tic­s' pro­tein de­grad­er take on AD­Cs for $100M up­front

Kyle LaHucik

Senior Reporter

Bris­tol My­ers Squibb is fur­ther dig­ging in­to the an­ti­body-drug con­ju­gate wave with a $100 mil­lion up­front deal for a dif­fer­ent take on the tech­nol­o­gy. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times